Mural Oncology Net Profit Margin 2023-2025 | MURA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Mural Oncology net profit margin from 2023 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Mural Oncology net profit margin from 2023 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$75.3B
Zoetis (ZTS)	$68.1B
Takeda Pharmaceutical (TAK)	$46.9B
Daiichi Sankyo, - (DSNKY)	$43.1B
BeOne Medicines - (ONC)	$29.6B
Sandoz Group AG (SDZNY)	$25B
Summit Therapeutics (SMMT)	$18.1B
Merck (MKKGY)	$16.5B
Shionogi (SGIOY)	$14.2B
United Therapeutics (UTHR)	$13.2B
Neurocrine Biosciences (NBIX)	$13B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.2B
Stevanato Group S.p.A (STVN)	$7.8B
Corcept Therapeutics (CORT)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$6.9B
Grifols, S.A (GRFS)	$6.7B
Ionis Pharmaceuticals (IONS)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.3B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$3.2B
Crinetics Pharmaceuticals (CRNX)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.8B
Ocular Therapeutix (OCUL)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B